Reimbursed Care Access in Côte d'Ivoire

Currently classified internationally as a Schedule I psychotropic substance under the 1971 UN Convention on Psychotropic Substances; no publicly available evidence of an approved medical program, national reimbursement pathway, or compassionate-use access for psilocybin in Côte d’Ivoire. Consequently, there is no documented national reimbursement or formal clinical access outside of authorised international-style clinical research. # #

Currently classified internationally as a Schedule I psychotropic substance under the 1971 UN Convention and is not documented as having an authorised medical program or reimbursement in Côte d’Ivoire; access would be limited to authorised clinical trials (if any) under national research approvals. No national reimbursement framework or licensed therapeutic MDMA programs were identified. # #

No public evidence was located of esketamine (Spravato) regulatory approval, inclusion on the national formulary, or public reimbursement in Côte d’Ivoire. The country’s national essential medicines list (published national list used in clinical procurement) lists ketamine (the racemate) as an essential general anaesthetic agent, but there are no national policy documents or health‑insurance reimbursement records found that indicate esketamine nasal spray has been registered or reimbursed by national schemes. For ketamine on the national essential medicines list, see the Côte d’Ivoire national list (kétamine entries). #

Ketamine is established and available in routine medical practice in Côte d’Ivoire as a general anaesthetic and is included on the national essential medicines list used for procurement and hospital formularies; this demonstrates formal medical availability for anaesthesia and emergency indications and implies government procurement/coverage in public hospitals rather than an experimental or restricted status. The national essential medicines list explicitly lists multiple injectable ketamine presentations (e.g., 10 mg/ml and 50 mg/ml) indicating standard clinical availability and inclusion in essential‑medicines procurement. Clinical use in Côte d’Ivoire follows the usual global pattern in low‑resource settings where ketamine is used for induction, procedural sedation, and emergency anesthesia; however, there is no public evidence that ketamine is reimbursed specifically for psychedelic-assisted psychotherapy programs or that payers reimburse off‑label psychiatric uses as part of a formal, standardized mental‑health benefit. Where ketamine is used clinically (operative anesthesia, emergency medicine), it is procured as an essential medicine by health facilities. #

Dimethyltryptamine (DMT) is internationally controlled (Schedule I under the 1971 UN Convention) and there is no documented medical/reimbursement framework for DMT in Côte d’Ivoire; any use is limited to approved clinical research under national research authorization if permitted. Preparations that contain DMT (e.g., ayahuasca brews) remain legally problematic because the active compound is controlled even when botanical sources are not explicitly listed under international treaty text. # #

5‑MeO‑DMT is treated in most jurisdictions as a controlled psychoactive tryptamine with no authorized medical-reimbursement pathway in Côte d’Ivoire; no national therapeutic approvals or reimbursement mechanisms were identified—access would be limited to approved clinical research if permitted. (No national policy or registration for therapeutic 5‑MeO‑DMT located.)

No evidence of an authorised medical or reimbursement pathway for ibogaine in Côte d’Ivoire; ibogaine is not part of the national essential medicines list and is generally treated as a prohibited/controlled psychoactive in many countries with access limited to research or underground contexts. Currently classified as a strictly controlled substance under national drug scheduling laws in most jurisdictions, with no authorized medical use outside of approved clinical research.

Because ayahuasca contains DMT (a Schedule I substance), decoctions containing significant DMT are effectively prohibited under international scheduling and there is no documented legal medical, reimbursed access pathway for ayahuasca in Côte d’Ivoire. Any ceremonial or therapeutic use would face the same legal controls applied to DMT unless a specific national religious exemption exists (none was identified). #

Mescaline and peyote derivatives are internationally controlled (mescaline is listed under international psychotropic controls) and there is no evidence of medical approval or reimbursement for mescaline in Côte d’Ivoire; access is effectively limited to authorised research if permitted by national authorities. #

Synthetic 2C‑series phenethylamines (commonly referred to as “2C‑X”) are broadly treated as controlled/illegal substances in most national drug control frameworks and have no documented medical approval or reimbursement pathway in Côte d’Ivoire; access is limited to approved clinical research where that is authorised. Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.